- Phase 3 study expected to enroll 6,000 participants starting in the Northern Hemisphere - Participants will include adults over 65 years of age in addition to individuals with high-risk co-morbidities and immune compromised status SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that the first participants have been dosed in its Phase 3 ...

Jay Olson from Oppenheimer sets a price target of $30 for Immuneering Corporation (NASDAQ:IMRX), indicating a significant potential upside.Immuneering announces an underwritten public offering of 18.96 million shares, aiming to raise approximately $175 million.The company's stock shows volatility, with a current decrease of 13.33%, amidst its efforts to strengthen its financial position through strategic financial activities.On September 25, 2025, Jay Olson from Oppenheimer set a price target of $30 for Imm ...

Intellia Therapeutics Inc. (NASDAQ: NTLA) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN).Results were presented at the International ATTR Amyloidosis Annual Meeting for Patients and Doctors. The results were simultaneously published in the New England Journal of Medicine.DataDeep, durable and consistent TTR reductions continue to be observed. Across ...

Key Takeaways BDTX's silevertinib targets 50 EGFR mutations, including C797S resistance seen after Tagrisso. Enrollment completed in frontline cohort; initial silevertinib data expected in Q4 2025. BDTX seeks FDA feedback in 2026 and potential partnerships for pivotal silevertinib studies.Black Diamond Therapeutics’ (BDTX) lead clinical-stage program, silevertinib (formerly BDTX-1535), is a brain penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting epidermal gro ...

LOS ANGELES, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming November 7, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) securities between March 7, 2024 and May 23, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR SAVARA INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOU ...

NEW ORLEANS, Sept. 25, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 17, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cytokinetics, Incorporated (NasdaqGS: CYTK), if they purchased or otherwise acquired the Company’s securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of ...

CAMP4 Therapeutics Corporation (CAMP) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Ind ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

PresentationCourtney BreenSanford C. Bernstein & Co., LLC., Research Division Fantastic. Hi, everyone. It's great to have you here today. Thank you so much for joining us. I am privileged to be sharing the stage with Rose Loughlin here from Moderna. For those of you who do not know me, my name is Courtney Breen. I cover the U.S. large cap names here at Bernstein. And we're hoping to have a bit of a conversation, particularly into the oncology portfolio at Moderna today. We're going to start first, though, ...

Key Takeaways RIGL's Tavalisse drove $68.5M sales in H1 2025, up 44% year over year, driving top-line growth.RIGL raised its 2025 revenue outlook to $270-$280M on strong performance across its marketed products.FOLD's Galafold posted $233.1M H1 2025 sales, up 11% year over year, with patent protection to 2038.Both Rigel Pharmaceuticals (RIGL) and Amicus Therapeutics (FOLD) are developing and commercializing treatments for rare medical conditions where existing therapies are limited, with the goal of establi ...